PDCD1 and neoplasm: Similar synergy was also demonstrated in a BRAFV600E/Pten(−/−) melanoma mouse model demonstrating prolonged survival and slowed tumour growth in mice treated with combined BRAFi and anti-PD-1 or anti-PD-L1, whereas anti-PD-(L)1 monotherapy failed to induce response [14].